10.7 RIDE/RISE
Summary
RIDE and RISE were parallel, 24-month, multinational, double-masked, sham-injection controlled, randomized phase 3 studies designed to evaluate the efficacy of ranibizumab in patients with DME. The studies enrolled 759 patients (RISE enrolled 377 patients; RIDE enrolled 382 patients) with confirmed vision loss as a result of DME. All enrolled patients had a BCVA between 20/40 and 30/320, and all enrolled patients had central subfield thickness of at least 275 microns (as confirmed on OCT).
Quiz Module 10.7
Attention: you are not signed in!
To validate your answers and keep track of your progress please sign in or register a new account
To validate your answers and keep track of your progress please sign in or register a new account
1. RIDE and RISE were designed to study efficacy and safety of:
2. Ranibizumab was the second anti-VEGF agent approved for DME, the first agent approved was: